Identification of a Spike-Specific CD8+ T-Cell Epitope Following Vaccination Against the Middle East Respiratory Syndrome Coronavirus in Humans

Caroline E. Harrer*, Leonie Mayer, MVA-MERS-S Study Group, Anahita Fathi, Susan Lassen, My L. Ly, Madeleine E. Zinser, Timo Wolf, Stephan Becker, Gerd Sutter, Christine Dahlke, Marylyn M. Addo*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Downloads (Pure)

Abstract

Licensed vaccines against the Middle East respiratory syndrome coronavirus (MERS-CoV), an emerging pathogen of concern, are lacking. The modified vaccinia virus Ankara vector-based vaccine MVA-MERS-S, expressing the MERS-CoV-spike glycoprotein (MERS-S), is one of 3 candidate vaccines in clinical development and elicits robust humoral and cellular immunity. Here, we identified for the first time a MERS-S-specific CD8+ T-cell epitope in an HLA-A∗03:01/HLA-B∗35:01-positive vaccinee using a screening assay, intracellular cytokine staining, and in silico epitope prediction. As evidence from MERS-CoV infection suggests a protective role of long-lasting CD8+ T-cell responses, the identification of epitopes will facilitate longitudinal analyses of vaccine-induced T-cell immunity.

Original languageEnglish
Pages (from-to)e327-e332
JournalJournal of Infectious Diseases
Volume230
Issue number2
DOIs
Publication statusPublished - 15 Aug 2024

Bibliographical note

Publisher Copyright:
© 2024 The Author(s).

Fingerprint

Dive into the research topics of 'Identification of a Spike-Specific CD8+ T-Cell Epitope Following Vaccination Against the Middle East Respiratory Syndrome Coronavirus in Humans'. Together they form a unique fingerprint.

Cite this